4.6 Article

A Prostate Cancer Nimbosus'': Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies

Journal

EUROPEAN UROLOGY
Volume 72, Issue 5, Pages 665-674

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.eururo.2017.04.034

Keywords

Intraductal carcinoma; Cribriform architecture; Genomic instability; Hypoxia; SChLAP1; Prognosis

Funding

  1. Movember funds through Prostate Cancer Canada
  2. Ontario Institute for Cancer Research - Government of Ontario
  3. Prostate Cancer Canada
  4. Movember Foundation [RS2014-01]
  5. Canadian Urologic Oncology Group Research Award
  6. National Medical Research Council Singapore Transition Award
  7. Terry Fox Research Institute New Investigator Award
  8. Prostate Cancer Canada Rising Star Fellowship
  9. CIHR New Investigator Award
  10. Canadian Institute for Health Research
  11. Ontario government
  12. Princess Margaret Cancer Centre Foundation
  13. Radiation Medicine Program Academic Enrichment Fund
  14. Canadian Cancer Society Research Scientist Award

Ask authors/readers for more resources

Background: Intraductal carcinoma (IDC) and cribriform architecture (CA) represent unfavorable subpathologies in localized prostate cancer. We recently showed that IDC shares a clonal ancestry with the adjacent glandular adenocarcinoma. Objective: We investigated for the co-occurrence of aggression'' factors, genomic instability and hypoxia, and performed gene expression profiling of these tumors. Design, setting, and participants: A total of 1325 men were treated for localized prostate cancer from four academic institutions (University Health Network, CHU de Quebec-Universite ' Laval, Memorial Sloan Kettering Cancer Center [MSKCC], and Erasmus Medical Center). Pathological specimens were centrally reviewed. Gene copy number and expression, and intraprostatic oxygenation were assessed. Outcome measurements and statistical analysis: IDC/CA was separately assessed for biochemical relapse risk in the Canadian and MSKCC cohorts. Both cohorts were pooled for analyses on metastasis. Results and limitation: Presence of IDC/CA independently predicted for increased risks of biochemical relapse (HRCanadian 2.17, p < 0.001; HRMSKCC 2.32, p = 0.0035) and metastasis (HRpooled 3.31, p < 0.001). IDC/CA + cancers were associated with an increased percentage of genome alteration (PGA [median] 7.2 vs 3.0, p < 0.001), and hypoxia (64.0% vs 45.5%, p = 0.17). Combinatorial genomic-pathological indices offered the strongest discrimination for metastasis (C-index 0.805 [clinical + IDC/CA + PGA] vs 0.786 [clinical + IDC/CA] vs 0.761 [clinical]). Profiling of mRNA abundance revealed that long noncoding RNA, SChLAP1, was the only gene expressed at >3-fold higher (p < 0.0001) in IDC/CA+ than in IDC/CAtumors, independently corroborated by increased SChLAP1 RNA in situ hybridization signal. Optimal treatment intensification for IDC/CA+ prostate cancer requires prospective testing. Conclusions: The poor outcome associated with IDC and CA subpathologies is associated with a constellation of genomic instability, SChLAP1 expression, and hypoxia. We posit a novel concept in IDC/CA+ prostate cancer, nimbosus'' (gathering of stormy clouds, Latin), which manifests as increased metastatic capacity and lethality. Patient summary: A constellation of unfavorable molecular characteristics co- occur with intraductal and cribriform subpathologies in prostate cancer. Modern imaging for surveillance and treatment intensification trials should be considered in this adverse subgroup. (C) 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available